Navigation Links
Study Finds Astaxanthin Is Potent Inhibitor of Oxidation in Cell Membrane Model

A just-published research study by Dr. R Preston Mason and colleagues at Elucida Research has determined that astaxanthin, a relatively //unknown carotenoid found in nature, shows significant promise as a viable scaffold for a new therapy to treat cardiovascular disease based on its exceptional antioxidant properties in membrane models.

Combined with published proof-of-concept, pre-clinical and anecdotal human data, the results of the Mason study (Differential effects of carotenoids on lipid peroxidation due to membrane interactions; xray diffraction analysis by McNulty et al.) signify that astaxanthin exhibits potential utility for use as the scaffold for antioxidant/anti-inflammatory agents in the treatment of cardiovascular and other chronic inflammatory diseases. An astaxanthin derivative may improve, or augment, the restoration of the cellular oxidation balance (i.e. redox status) of mitochondria and cell signaling pathways upstream from the point that produces activation of bioactive inflammatory mediators.

"These data clearly demonstrate a differentiation within the carotenoid class of medically promising antioxidants and provided, in part, the impetus for Cardax Pharmaceuticals to advance an astaxanthin-based derivative into an IND development program,” according to Fredric Pashkow, Executive Vice President and Chief Medical Officer of the Company and former head of U.S. Medical Affairs for cardiovascular drugs at Sanofi-Aventis.

Pashkow also said that the work from Mason’s lab suggests astaxanthin could provide a platform for discovery of an entirely new class of safe, cardiovascular drugs. “These potent antioxidants may be the third big wave in the modern therapy for the secondary prevention of heart attack and stroke. In the heart, these agents probably will work by recalibrating the cellular oxidation balance in order to blunt the cell and tissue inflammatory response to injury and limit damage to the myocardium.”

In addition, by limiting the amount of oxidative damage to LDL, the “bad cholesterol,” an astaxanthin derivative could alter the progress of atherosclerosis, the underlying inflammatory process that clogs arteries and is responsible for most heart attacks and strokes when an atherosclerotic plaque ruptures.

Pashkow maintains that statins represented the “first big wave” of cardiovascular preventive therapy. They proved to lower the risk of a second heart attack or cardiovascular death by 45% over 5 years, though more than half of the people treated did not realize their benefit. Increasing the dose of the statin improves the outcome and extends the benefits to people who have risk factors alone such as high cholesterol, but dose limiting side effects emerge especially when the drugs are taken for a long time. Pashkow said that the recent problems encountered with Pfizer’s torcetrapib highlight the impact of a late stage pipeline non-approval combined with the looming patent expiry of the current market leading therapy.

Antiplatelet therapies, particularly aspirin and aspirin in combination with other antiplatelet agents represent the “second big wave” of preventive therapies following a heart attack. In combination, they reduce the risk of future heart attacks and strokes by about 30% over a one-year period.

However, an appreciable segment of the population are 'resistant' to antiplatelet therapy and remain relatively unprotected. More potent antiplatelet therapies, or increased doses of aspirin increase the risk of bleeding. “This wave of treatments,” said Pashkow “may be peaking as well.”

Cardax Pharmaceuticals is exploring the use of astaxanthin and novel astaxanthin derivatives, as well as other carotenoids, for use as medical therapeutics (i.e. antioxidant/anti-inflammatory) in disease states characterized by abnormal cellular oxidation and chronic inflammation (e.g. cardiovascular, liver, ocular, prostatic and neurodegenerative diseases).


Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:

(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation claim ... of hospital and nonhospital care, according to a recent study by the Workers Compensation ... Edition , found medical payments per claim with more than seven days of lost ...
(Date:12/1/2015)... ... 01, 2015 , ... It’s official: Tattoo taboo is a thing of the ... among Millennials (a whopping one in three aged 18 to 25 is inked). As ... with their ink. In fact, RealSelf , the world’s largest community for learning ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, ... Healthcare was recognized as a finalist in the category of Digital Solutions for ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Breg, Inc ., a premier provider ... it has been awarded three contracts by Novation, a ... will have access to improved pricing for Breg,s portfolio ... goods dedicated to advancing orthopedic care.  ... population, rising prevalence of chronic conditions and the health ...
(Date:12/1/2015)... 2015 During the recent 2015 Transcatheter ... Francisco, CA , Medinol Ltd. continued to ... During a satellite symposium, "The BioNIR eDES: The ... Restenosis", a renowned physician panel discussed the key ... Coronary Stent System and the Medinol eDES Coronary ...
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
Breaking Medicine Technology: